Skip to main content

First Weight-Loss Pill From Lilly, Orforglipron, Shows Promising Results

Medically reviewed by Carmen Pope, BPharm. Last updated on April 18, 2025.

By I. Edwards HealthDay Reporter

FRIDAY, April 18, 2025 — A new pill designed to help with weight loss and blood sugar control is showing promise in early studies.

Eli Lilly said its experimental drug, orforglipron, helped people with type 2 diabetes lower their blood sugar and lose weight. The company is hoping to bring the first GLP-1 weight-loss pill to market, The Wall Street Journal said.

GLP-1 drugs, such as Ozempic and Wegovy, are popular for helping people manage diabetes and lose weight. But right now, they are only available as injections.

Doctors and patients have been hoping for a pill version that would be easier to take.

“It really gives us an opportunity to reach many more patients than you can reach with an injectable,” Jeffrey Emmick, senior vice president of product development at Lilly Cardiometabolic Health, told The Wall Street Journal.

Some people don’t like injections, and injectable drugs often need to be kept cold. The pill version could help more people around the world who don’t have easy access to refrigeration.

It may also be easier to produce in large amounts. Lilly’s injectable GLP-1 drug went into shortage shortly after it was released.

In the new study, orforglipron was tested for 40 weeks in adults with type 2 diabetes. People who took the highest dose lost an average of 16 pounds, or about 7.9% of their body weight. The most common side effects were stomach-related and were mostly mild or moderate, Lilly said.

The company plans to submit the pill for approval as a weight-loss treatment by the end of 2025 and for diabetes treatment in 2026.

The drug works by targeting the GLP-1 hormone, which helps regulate blood sugar and reduce appetite. Unlike other GLP-1 drugs that are made from large molecules, orforglipron is a small molecule. That means the body may absorb it more easily, The Wall Street Journal reported.

Other companies, including Novo Nordisk and Pfizer, are also developing GLP-1 pills. Experts expect the obesity drug market to grow to more than $100 billion by the end of the decade.

For more information, see What is orforglipron?

Sources

  • The Wall Street Journal, April 17, 2025

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted April 2025

Read this next

FDA and Novo Nordisk Alert Consumers to Counterfeit Ozempic

MONDAY, April 21, 2025 -- The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout for counterfeit Ozempic...

Pregnancy Complications Affect Future Heart Health

FRIDAY, April 18, 2025 -- Complications during pregnancy can mean a woman’s future heart health is at risk, particularly if she is overweight or obese, a new study...

Pfizer Ends Testing of Obesity Pill, Danuglipron, After Possible Liver Injury

TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury. The...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.